Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3
InChI
InChIKey=MFFMDFFZMYYVKS-SECBINFHSA-N
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17352677
Curator's Comment: # Merck in 1999
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17580730 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | JANUVIA Approved UseJANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Important Limitations of Use: •JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1.2) •JANUVIA has not been studied in patients with a history of pancreatitis. (1.2, 5.1) 1.1 Monotherapy and Combination Therapy JANUVIA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See Clinical Studies (14). Launch Date2006 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
950 nM |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.52 μM × h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15, 30 |
no [IC50 >100 uM] | no (co-administration study) Comment: results indicated that sitagliptin was not a time-dependent inhibitor of CYP3A4; sitagliptin did not meaningfully alter the pharmacokinetics of simvastatin. Page: 15, 30 |
||
Page: 6.0 |
no | |||
Page: 15.0 |
no | |||
Page: 6.0 |
no | |||
Page: 9.0 |
no | |||
Page: 15.0 |
no | no (co-administration study) Comment: sitagliptin had no inhibitory effect on the P-gp mediated transport of digoxin, verapmil, ritonavir, adn vinblastine Page: 15.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
inconclusive | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 4, 42 |
yes | |||
Page: 4, 42 |
yes | |||
Page: 4, 15 |
yes | |||
Page: 4, 15 |
yes | yes (co-administration study) Comment: cyclosporin A significantly inhibited P-gp transport of sitagliptin Page: 4, 15 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 22, 23 |
PubMed
Title | Date | PubMed |
---|---|---|
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. | 2005 |
|
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors. | 2005 Aug |
|
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. | 2005 Summer |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | 2006 Dec |
|
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | 2006 Dec |
|
First-in-class diabetes drug approved. | 2006 Dec 1 |
|
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | 2006 Jun |
|
DPP-4 inhibitors and their potential role in the management of type 2 diabetes. | 2006 Nov |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | 2006 Nov |
|
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. | 2006 Sep |
|
The burden of type 2 diabetes: strategies to prevent or delay onset. | 2007 |
|
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. | 2007 |
|
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. | 2007 Apr |
|
Characterization of two cyclic metabolites of sitagliptin. | 2007 Apr |
|
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. | 2007 Aug |
|
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | 2007 Aug |
|
Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. | 2007 Dec 15 |
|
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | 2007 Jan |
|
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 Jan 1 |
|
New treatment for diabetes. | 2007 Jan-Feb |
|
Management of comorbid diabetes and cancer. | 2007 Jul |
|
[New concepts in the treatment of type 2 diabetes]. | 2007 Jul |
|
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. | 2007 Jun |
|
Sitagliptin/metformin (Janumet) for type 2 diabetes. | 2007 Jun 4 |
|
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | 2007 Mar |
|
Treatment of type 2 diabetes mellitus and the incretin system. | 2007 May |
|
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. | 2007 May |
|
New treatments for diabetes. | 2007 May 24 |
|
New treatments for diabetes. | 2007 May 24 |
|
New treatments for diabetes. | 2007 May 24 |
|
[The incretin effect: a new therapeutic target in type 2 diabetes]. | 2007 Sep |
|
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. | 2007 Sep |
|
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | 2007 Sep |
|
Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. | 2008 Feb |
|
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. | 2008 Feb |
|
How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment. | 2008 Jan |
|
Dipeptidyl peptidase IV inhibitors and diabetes therapy. | 2008 Jan 1 |
Sample Use Guides
100 mg once daily. It can be taken with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23849976
Curator's Comment: Sitagliptin therapy enhances circulating angiogenic cell numbers, angiogenesis and blood flow in the critical limb ischemia area.
Adipose tissue from adult-male Fischer 344 rats were cultured in endothelial progenitor cell culture medium for 14 d with (25 μmol/L) or without sitagliptin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:44:18 GMT 2025
by
admin
on
Wed Apr 02 08:44:18 GMT 2025
|
Record UNII |
QFP0P1DV7Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-VATC |
QA10BD12
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-VATC |
QA10BH51
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
NDF-RT |
N0000175913
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-ATC |
A10BH51
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-ATC |
A10BD07
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
NDF-RT |
N0000175912
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-ATC |
A10BD24
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
LIVERTOX |
NBK548083
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-ATC |
A10BH01
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-VATC |
QA10BD07
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-VATC |
QA10BH01
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
||
|
WHO-ATC |
A10BD12
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
486460-32-6
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
QFP0P1DV7Z
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
100000091875
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
C73838
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
DTXSID70197572
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
8692
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
Sitagliptin
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
7516
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1422
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
SUB25227
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
4369359
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
C496398
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
593411
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
SITAGLIPTIN
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
6286
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
JK-166
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
DB01261
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
m9960
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
QFP0P1DV7Z
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
2448
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY | |||
|
40237
Created by
admin on Wed Apr 02 08:44:18 GMT 2025 , Edited by admin on Wed Apr 02 08:44:18 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
RACEMATE -> ENANTIOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
DOSE |
|
||